🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,557 results for “placebo” Clear

  1. Benralizumab Placebo for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (APFS) for subcutaneous injection. Please refer to the IMPD documentation enclosed., Placebo, Fasenra 30 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Hypereosinophilic Syndrome (HES)

    phase 3 small molecule active

    1 trial
  2. Bexicaserin, LP352 (bexicaserin) Placebo Oral Solution

    Lacuna Pharma Pty Ltd

    Dravet Syndrome

    phase 3 small molecule active

    1 trial
  3. Bexotegrast, Placebo matching PLN-74809

    PLIANT THERAPEUTICS, INC.

    Idiopathic pulmonary fibrosis (IPF)

    phase 3 small molecule active

    1 trial
  4. Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 320 mg solution for injection in pre-filled pen, Bimzelx 320 mg solution for injection in pre-filled pen, Placebo matching test. 0.9% sodium chloride solution for injection (unauthorized)., Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled syringe

    Lacuna Pharma Pty Ltd

    Palmoplantar Pustulosis

    phase 3 small molecule active

    1 trial
  5. Bitopertin, Matching Placebo

    Disc Medicine

    X-Linked Protoporphyria (XLP), Erythropoietic Protoporphyria (EPP)

    phase 3 small molecule active

    1 trial
  6. Bocouture, Placebo excipients (sucrose and human serum albumin) are reconstituted with sterile saline. Placebo vials will have identical appearance as the active product vials.

    Merz Therapeutics GmbH

    Moderate to Severe Platysma Prominence

    phase 3 small molecule active

    1 trial
  7. CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, PLACEBO, CASDATIFAN

    Arcus Biosciences

    Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial
  8. CHAMPIX 0.5 mg film-coated tablets, Placebo CHAMPIX ® 0.5mg Comprimé pelliculé

    Pari Pharma GmbH

    Smokers smoking at least 10 cigarettes/day in the past year

    phase 3 small molecule active

    1 trial
  9. CHF6001 DPI, CHF6001 DPI, Placebo to match CHF6001 DPI

    Chiesi Farmaceutici S.p.A

    Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis

    phase 3 small molecule active

    1 trial
  10. CISPLATIN , PACLITAXEL , GEMCITABINE , CARBOPLATIN , placebo for mRNA-4157, PEMETREXED , mRNA-4157, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial
  11. CISPLATIN, Armisarte 25 mg/ml concentrate for solution for infusion, CARBOPLATIN, PEMETREXED, TAGRISSO 80 mg film-coated tablets, PLACEBO, TAGRISSO 40 mg film-coated tablets

    AstraZeneca AB

    Patients with histologically or cytologically documented non-squamous NSCLC with completely resectable (Stage II - IIIB N2) disease

    phase 3 small molecule active

    1 trial
  12. CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS, Placebo to Clostridium Botulinum neurotoxin type A (150 kD)

    Merz Therapeutics GmbH

    Episodic migraine

    phase 3 small molecule active

    1 trial
  13. COPINAL 300 mg cápsulas, Placebo has the same composition than imp except the active substance

    The George Institute

    Chronic liver disease

    phase 3 small molecule active

    1 trial
  14. CORTANCYL 20 mg, comprimé sécable, Placebo of CORTANCYL 20 mg

    Pari Pharma GmbH

    Adults patients with isolated acute urticaria presenting to the emergency department

    phase 3 small molecule active

    1 trial
  15. CORTANCYL 20 mg, comprimé sécable, placebo of Cortancyl 20 mg, NaCl 0,9% as placebo of kineret, Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe.

    Pari Pharma GmbH

    Men and women over 18 years of age with renal failure renal failure stages 3b/4/5, renal transplantation or dialysis and an untreated gout attack

    phase 3 small molecule active

    1 trial
  16. CS1003, Placebo, LENVATINIB

    Lacuna Pharma Pty Ltd

    Unresectable advanced hepatocellular carcinoma

    phase 3 small molecule active

    1 trial
  17. Calquence 100 mg hard capsules, CYCLOPHOSPHAMIDE, RITUXIMAB, DOXORUBICIN, Placebo, 100mg hard capsules; Identical to IMP apart from the active substance, VINCRISTINE, PREDNISONE

    Lacuna Pharma Pty Ltd

    Diffuse large B-cell lymphoma

    phase 3 small molecule active

    1 trial
  18. Capivasertib, Faslodex 250 mg solution for injection., Placebo to Capivasertib, Capivasertib

    AstraZeneca AB

    Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer

    phase 3 small molecule active

    1 trial
  19. Capivasertib, Placebo for capivasertib film-coated tablet for oral use, ABIRATERONE ACETATE, Capivasertib

    AstraZeneca AB

    Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency

    phase 3 small molecule active

    1 trial
  20. Carbetocin Nasal Spray, Placebo to match carbetocin 11.4 mg/ml (2ml /vial)

    Lacuna Pharma Pty Ltd

    Hyperphagia related behaviour associated with Prader-Willi Syndrome (PWS)

    phase 3 small molecule active

    1 trial
  21. CardiolRx™ Placebo is a non-aqueous solution of medium chain triglycerides with 1.0% vitamin E as anti-oxidant. CardiolRx™ Placebo is a pale yellow clear liquid. The CardiolRx™ Placebo product is essentially the same as the CardiolRx™ drug product with the exception that the placebo does not include the active drug substance, cannabidiol., CardiolRx

    Cardiol Therapeutics

    Recurrent Pericarditis

    phase 3 small molecule active

    1 trial
  22. Cenerimod 4 mg, Cenerimod matching placebo

    Viatris Pharmaceuticals Co.,

    Moderate to severe systemic lupus erythematosus

    phase 3 small molecule active

    1 trial
  23. Cenerimod matching placebo, Cenerimod 4 mg

    Viatris Pharmaceuticals Co.,

    Moderate to severe systemic lupus erythematosus

    phase 3 small molecule active

    1 trial
  24. Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo 15mg tablets, venglustat GZ402671 - SAR402671, Placebo 6mg tablets, Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo for Cerezyme, Cerezyme 400 Units Powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671

    Sanofi-aventis Healthcare Pty Ltd

    Gaucher's disease type III

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources